PALI-2108
Ulcerative Colitis
Key Facts
About Palisade Bio
Palisade Bio is advancing a novel prodrug platform to create safer, more effective oral therapies for chronic inflammatory and fibrotic diseases, with an initial focus on inflammatory bowel disease (IBD). The company's lead program, PALI-2108, is a once-daily oral PDE4 inhibitor prodrug engineered for selective bioactivation in the ileum and colon, aiming to maximize local efficacy and minimize systemic adverse events. Palisade is preparing to initiate a Phase 2 study in ulcerative colitis, marking a critical inflection point for validating its targeted delivery approach. The strategy leverages proven PDE4 biology to address significant unmet needs in large, chronic disease markets.
View full company profileAbout Palisade Bio
Palisade Bio is advancing a novel prodrug platform to create safer, more effective oral therapies for chronic inflammatory and fibrotic diseases, with an initial focus on inflammatory bowel disease (IBD). The company's lead program, PALI-2108, is a once-daily oral PDE4 inhibitor prodrug engineered for selective bioactivation in the ileum and colon, aiming to maximize local efficacy and minimize systemic adverse events. Palisade is preparing to initiate a Phase 2 study in ulcerative colitis, marking a critical inflection point for validating its targeted delivery approach. The strategy leverages proven PDE4 biology to address significant unmet needs in large, chronic disease markets.
View full company profileTherapeutic Areas
Other Ulcerative Colitis Drugs
| Drug | Company | Phase |
|---|---|---|
| BB265 | BiomeBank | Phase 1 |
| ALTB-268 | AltruBio | Phase IIa |
| AIM-HI-UC | PathAI | Clinical Trials |
| Patient Stratification in Ulcerative Colitis | Enable Medicine | Research |
| Mesalazine (Lifecycle Management) | Dr. Falk Pharma | Approved/Phase 3 |
| AhR Agonist Program | Azora Therapeutics | Phase 1b |
| R-3750 | Virtici | Phase 1 |
| GPR35 Inhibitor | ThirtyFiveBio | Preclinical |
| BT-600 | Biora Therapeutics | Phase 1 |
| Asacol® (mesalazine) | Tillotts Pharma | Approved |
| MB310 | Microbiotica | Phase 1b |
| '1805 | Revolo Biotherapeutics | Phase 2 (Planned) |